Mezigdomide

Mezigdomide is a cereblon E3 ligase modulator developed by Bristol Myers Squibb to treat multiple myeloma.^{[1][2][3][4][5]}

Mezigdomide

Legal status
Legal status	Investigational
Identifiers
IUPAC name 4-[4-[[4-[[2-[(3S)-2,6-Dioxopiperidin-3-yl]-1-oxo-3H-isoindol-4-yl]oxymethyl]phenyl]methyl]piperazin-1-yl]-3-fluorobenzonitrile
CAS Number	2259648-80-9
PubChem CID	137379043
ChemSpider	84451594
UNII	LA88IH4O02
ChEMBL	ChEMBL4648616
Chemical and physical data
Formula	C32H30FN5O4
Molar mass	567.621 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CC(=O)NC(=O)[C@H]1N2CC3=C(C2=O)C=CC=C3OCC4=CC=C(C=C4)CN5CCN(CC5)C6=C(C=C(C=C6)C#N)F
InChI InChI=1S/C32H30FN5O4/c33-26-16-23(17-34)8-9-27(26)37-14-12-36(13-15-37)18-21-4-6-22(7-5-21)20-42-29-3-1-2-24-25(29)19-38(32(24)41)28-10-11-30(39)35-31(28)40/h1-9,16,28H,10-15,18-20H2,(H,35,39,40)/t28-/m0/s1 Key:YTINZZFBHWSAGL-NDEPHWFRSA-N